ArticleActa pharmaceutica Sinica. B2020
Functional nano-vector boost anti-atherosclerosis efficacy of berberine in
Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Systematic review of Chinese medicine for the treatment of atherosclerosis.Frontiers in cardiovascular medicine · 2025Pooled it
- Berberine-associated lipid-inflammatory regulation in atherosclerosis: an integrative transcriptomic, single-cell, and in vivo study.Functional & integrative genomics · 2026Article
- Panax quinquefolium saponin decreases atherosclerosis in ovariectomized ApoEChinese medicine · 2026Article
- Emerging nanotechnological strategies for delivering bioactive components from botanical drugs and traditional Chinese medicine in atherosclerosis therapy: from formulation to mechanism.Frontiers in pharmacology · 2026Review
- The impact of dyslipidemia on skeletal health - from an immunoregulatory perspective.Frontiers in immunology · 2026Review
- Enhancing the Therapeutic Efficacy of Berberine and Quercetin Through Salt Formulation for Liver Fibrosis Treatment.International journal of molecular sciences · 2025Article
- Exosomes-Based Nanotherapeutic Strategies: An Important Approach for Spinal Cord Injury Repair.International journal of nanomedicine · 2025Review
- Targeted nanoparticles triggered by plaque microenvironment for atherosclerosis treatment through cascade effects of reactive oxygen species scavenging and anti-inflammation.Journal of nanobiotechnology · 2024Article
- ROS-Induced Endothelial Dysfunction in the Pathogenesis of Atherosclerosis.Aging and disease · 2024Review
- Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects.Acta pharmaceutica Sinica. B · 2023Article
- Berberine improves central memory formation of CD8Acta pharmaceutica Sinica. B · 2023Article
- Endothelial METRNL determines circulating METRNL level and maintains endothelial function against atherosclerosis.Acta pharmaceutica Sinica. B · 2023Article
- Advances in imaging and treatment of atherosclerosis based on organic nanoparticles.APL bioengineering · 2022Review
- Small molecule-assisted assembly of multifunctional ceria nanozymes for synergistic treatment of atherosclerosis.Nature communications · 2022Article
- Lycopene-Loaded Bilosomes Ameliorate High-Fat Diet-Induced Chronic Nephritis in Mice through the TLR4/MyD88 Inflammatory Pathway.Foods (Basel, Switzerland) · 2022Article
- Article
- Natural drugs targeting inflammation pathways can be used to treat atherosclerosis.Frontiers in pharmacology · 2022Review
- ROS-Based Nanoparticles for Atherosclerosis Treatment.Materials (Basel, Switzerland) · 2021Review
- Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.NPJ biofilms and microbiomes · 2021Article
- Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is the leading cause of heart attacks, stroke, and peripheral vascular disease. Berberine (BBR), a botanical medicine, has diversified anti-atherosclerotic effects but with poor absorption. The aim of this study was to develop an effective BBR-entrapped nano-system for treating AS in high-fat diet (HFD)-fed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.